QU

QuantaMatrix Incorporated

IVD specialist in rapid antimicrobial susceptibility testing for critical infections like sepsis.

317690 | KO

Overview

Corporate Details

ISIN(s):
KR7317690006
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 131 B동 16층(가산동, 비와이씨하이시티), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

QuantaMatrix Inc. is an in-vitro diagnostics (IVD) company specializing in innovative solutions for clinical microbiology. The company develops and manufactures medical devices that utilize proprietary technologies, including time-lapse microscopic imaging and microfluidics, to accelerate pathogen identification and antimicrobial susceptibility testing (AST). Its primary focus is on critical infections such as sepsis, with its dRAST™ (direct Rapid Antimicrobial Susceptibility Test) system designed to provide results significantly faster than conventional methods. By enabling quicker and more accurate diagnoses, QuantaMatrix aims to improve patient outcomes, facilitate timely antibiotic treatment, and help combat antimicrobial resistance. The company's platforms also serve molecular and immunoassay applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 881.8 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 5.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 80.3 KB
2025-07-17 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.6 KB
2025-07-15 00:00
Share Issue/Capital Change
전환청구권행사
Korean 8.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]수시공시의무관련사항(공정공시) (유상증자 계획)
Korean 11.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 960.9 KB
2025-03-28 00:00
AGM Information
정기주주총회결과
Korean 24.1 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 167.0 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-12 00:00
Legal Proceedings Report
파생상품거래손실발생
Korean 6.8 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.9 KB

Automate Your Workflow. Get a real-time feed of all QuantaMatrix Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for QuantaMatrix Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for QuantaMatrix Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Epitomee Medical Ltd. Logo
Develops ingestible therapeutic devices for weight management and targeted drug delivery.
Israel
EPIT
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.